Compare AbbVie Inc (ABBV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Regeneron Pharmaceuticals Inc — how do they compare? AbbVie Inc trades at $248.11 (market cap $438.19B), while Regeneron Pharmaceuticals Inc trades at $809.03 (market cap $83.19B). The key difference: AbbVie Inc is far larger — about 5.3× Regeneron Pharmaceuticals Inc's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | REGN | |
|---|---|---|
Market Cap | $438.19B | $83.19B |
Sector | Health | Health |
52-Week High | $263.58 | $812.27 |
52-Week Low | $197.38 | $545.94 |
Enterprise Value | $502.45B | $77.90B |
Dividend Yield | 2.79% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.47, up 0.99% with a bullish technical signal supported by moving averages and oversold RSI levels. The company demonstrates strong revenue growth with 2025 revenue reaching $61.16B and consistent earnings beats in recent quarters. Recent positive clinical trial results for ovarian cancer treatment and institutional accumulation signal confidence in the company's pipeline and growth trajectory.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 consensus price target offering 13% upside. Key risks include patent cliffs in the 2030s and high debt levels, but robust immunology portfolio growth and dividend aristocrat status provide stability. The stock's current valuation metrics suggest premium pricing relative to historical levels.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
